RELapses PrevENTion In Chronic Autoimmune Disease: Common Mechanisms And Co-morbidities (RELENT)
Funder
National Health and Medical Research Council
Funding Amount
$499,837.00
Summary
Treatment of people with chronic autoimmune and inflammatory diseases is not optimal, as we do not know how intensively to treat people, and current treatments often have significant side effects. The RELENT program aims, using multiple approaches, to gain a deeper and more useful knowledge of why these diseases are occuring, what might indicate that disease requires more treatment, and which treatments will be most targeted and have the fewest side effects.
Multiple Sclerosis Therapy: Human Pluripotent Stem Cell-Derived Neural Precursor Cells
Funder
National Health and Medical Research Council
Funding Amount
$1,775,225.00
Summary
Treatments for Multiple Sclerosis (MS) often have unsatisfactory outcomes. The limited ability of the body to repair damaged nerve tissue highlights a critically important need for MS patients. The long-term goal of our research is to develop a stem cell-based therapy that halts disease progression and repairs damaged nerve tissue. Research efforts will refine techniques to make safe and clinically-compatible cells from human stem cell lines and verify the therapeutic activity of these cells.
NOX Enzymes As Mediators Of Inflammation-triggered Neurodegeneration: Modulating NOX Enzymes As Novel Therapies
Funder
National Health and Medical Research Council
Funding Amount
$994,846.00
Summary
The NEURINOX project aims at identifying novel therapeutic targets for neurodegenerative diseases; an increasing health issue for the ageing Australian population. NADPH oxidases (NOX) enzymes, generate reactive oxygen species, and are key regulators of neuroinflammation. Inflammatory dysregulation is characterized by a change in NOX activity. NEURINOX will expound the links between neuroinflammation, NOX enzyme activity & neurodegenerative diseases to identify novel therapeutic targets to treat ....The NEURINOX project aims at identifying novel therapeutic targets for neurodegenerative diseases; an increasing health issue for the ageing Australian population. NADPH oxidases (NOX) enzymes, generate reactive oxygen species, and are key regulators of neuroinflammation. Inflammatory dysregulation is characterized by a change in NOX activity. NEURINOX will expound the links between neuroinflammation, NOX enzyme activity & neurodegenerative diseases to identify novel therapeutic targets to treat neuroinflammation.Read moreRead less